Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares at an average price of $425.63, resulting in a significant 96.85% decrease in their ownership to just 130 shares.
• The company's recent earnings report showed a missed EPS estimate with $6.41 reported, compared to the consensus estimate of $6.80, despite a revenue growth of 11.7% year-over-year.
• Analysts show varied opinions on the stock, with price targets ranging from $330 to $575 and a consensus rating of "Moderate Buy".

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $425.63, for a total value of $1,702,520.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at $55,331.90. This represents a 96.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $419.21 on Wednesday. The business has a fifty day moving average price of $347.95 and a two-hundred day moving average price of $316.38. The stock has a market capitalization of $18.91 billion, a PE ratio of 16.36, a P/E/G ratio of 6.47 and a beta of 0.62. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $442.01.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the business posted $5.85 EPS. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently made changes to their positions in the stock. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC acquired a new stake in United Therapeutics in the first quarter valued at approximately $32,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 10th. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Finally, Royal Bank Of Canada started coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an "outperform" rating and a $569.00 price objective on the stock. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.